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ABSTRACT
A simplified schedule of high-dose chemotherapy consisting of cyclophosphamide (60 mg · kg1 · d1 for 2
days), etoposide (15 mg · kg1 · d1 for 2 days), and carboplatin (400 mg/m2 per day for 2 days) plus autologous
non-cryopreserved peripheral blood stem cells (PBSCs) was used for treatment of patients with relapsed (n 
25) and refractory (n  3) Hodgkin disease. The use of such PBSCs mobilized by granulocyte colony-
stimulating factor after high-dose myeloablative therapy resulted in a rapid, complete, and sustained hemato-
poietic recovery. The median time to achieve an absolute neutrophil count >0.5  109/L was 13 days (range,
7-18 days). The median time to a self-sustained platelet count >20  109/L was 15 days (range, 7-20 days).
Twelve of the 28 patients (43%) were alive and without disease at a median follow-up of 16 months (range, 9-86
months) for all surviving patients. The estimated 2-year overall survival and disease-free survival for all patients
were 45% and 42%, respectively. Thirteen patients died of relapse or progressive disease, 2 died of infection,
and 1 was still surviving in relapse by the time of the analysis. The median time to relapse was 10 months
(range, 3-28 months) from PBSC infusion. High-dose chemotherapy with short-duration chemotherapy and
non-cryopreserved bone marrow is an effective and safe treatment modality for patients with relapsed or
resistant Hodgkin lymphoma.
© 2006 American Society for Blood and Marrow Transplantation
KEY WORDS
High-dose chemotherapy ● Resistant Hodgkin disease ● Relapsed Hodgkin disease ● Non-
cryopreserved peripheral blood stem cells ● Peripheral blood stem cell transplantation
v
p
i
m
i
b
s
t
p
w
c
oNTRODUCTION
Approximately 60% to 70% of patients with ad-
anced Hodgkin disease (HD) can be cured with com-
ination chemotherapy [1,2]. However patients who
elapse after attaining a complete remission (CR) with
hemotherapy or who do not respond to induction
hemotherapy and have primary refractory disease are
arely cured with conventional salvage chemotherapy
r salvage radiotherapy [3,4]
High-dose therapy followed by autologous stem
ell transplantation has been shown to produce long-
erm disease-free survival (DFS) in selected patients
ith advanced refractory HD [5,6]. However, the con- w
42entional procedures for collection and freezing of
eripheral blood stem cells (PBSCs) are time-consum-
ng and expensive [7] and methods to simplify bone
arrow transplantation procedures are needed mainly
n developing countries
Hematopoietic stem cells appear to maintain via-
ility for several days after collection if carefully
tored. Preti et al [8], in a nonrandomized retrospec-
ive analysis, compared the engraftment kinetics of 54
atients who received cryopreserved marrow cells
ith those of 45 patients who received refrigerated
ells. The refrigerated cells were stored for a median
f 4 days (range, 3-9 days). The cryopreserved cells
ere stored a median of 69 days (range, 5-981 days) at
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High-Dose Chemotherapy/PBSC Rescue for Refractory/Relapsed HD 94380°C using a cryopreserving mixture of dimethyl-
ulfoxide and hydroxyethyl starch. No signiﬁcant dif-
erence in engraftment kinetics was found between the
groups [8].
Refrigerated storage was supplanted by cryo-
reservation because most transplantation centers de-
elop multiday conditioning regimens. There is lim-
ted experience with autologous transplantation of
on-cryopreserved hematopoietic stem cells. We
resent the results of 28 patients with Hodgkin lym-
homa who were preconditioned with cyclophospha-
ide, etoposide, and carboplatin and received non-
ryopreserved unmanipulated PBSC transplantation
PBSCT) for their advanced or refractory disease.
ETHODS
Between 1996 and 2004, 28 patients with relapsed
r refractory HD underwent high-dose therapy and
utologous PBSCT at the Bone Marrow Transplant
nit of the Faculty of Medicine, Mansoura University
Mansoura, Egypt). The diagnosis and histologic sub-
ype of HD were based on biopsy results.
tudy Definitions and Evaluation
Patients were deﬁned to have induction failure if
hey had received induction chemotherapy with or
ithout salvage therapy and were never documented
o be in a CR. A sensitive relapse was deﬁned as50%
eduction in the bidimensional measurements of the
isease with the use of conventional salvage chemo-
herapy or radiotherapy. A resistant relapse was de-
ned as 50% reduction in the size of the tumor with
he use of conventional salvage chemotherapy or ra-
iotherapy. The duration of initial remission was cal-
ulated from time of documented CR to time of re-
apse.
Patients were clinically restaged at the time of
ntry into the study. Restaging procedures were re-
eated at day30, day90 after transplantation, or as
linically indicated. Follow-up tumor restaging was
erformed every 3 to 6 months for 2 years and then
early unless recurrence was suspected. Patients who
urvived to at least day 30 and had no evidence of
umor by clinical and radiologic evaluation for 1
onth were classiﬁed as having a CR. Patients who
ere received transplants in CR without evidence of
isease were considered to be in continuous CR after
ransplantation. Partial remission (PR) was deﬁned as
reduction 50% of measurable disease for 1
onth.
atient Selection
Patients were eligible for PBSCT if they did not
chieve CR after ﬁrst-line chemotherapy (induction
ailure) or if they had relapsed after a standard che- botherapy regimen. Patients whose ﬁrst relapse oc-
urred 12 months after completion of induction
hemotherapy were not candidates for transplantation
nless they did not respond to standard salvage che-
otherapy or had relapse at extranodal sites. Addi-
ional eligibility criteria included age 60 years,
arnofsky Performance Status score70, left ventric-
lar ejection fraction50%, forced expiratory volume
n 1 second 50%, and no major organ dysfunction
nrelated to their underlying lymphoma.
The patient characteristics at time of diagnosis are
isted in Table 1. The median age was 30 years (range,
6-50 years). There were 19 males and 9 females.
ifteen patients (54%) had stage III disease, 8 patients
28%) had stage IV disease, and 12 patients (43%) had
B” symptoms at time of diagnosis. Nine patients
32%) had extranodal involvement at diagnosis. The
athologic examination revealed lymphocytic pre-
ominance in 2 patients (7%), nodular sclerosis in 5
atients (18%), mixed cellularity in 13 patients (46%),
nd lymphocyte depletion in 8 patients (29%). Bone
arrow involvement was detected in 7 patients (25%).
Details of prior therapy are presented in Table 2.
ll patients were treated with induction chemotherapy
or a minimum of 3 cycles or until they had achieved
CR or minimal disease state. The median number of
rior chemotherapy regimens was 4 (range, 3-8). Four
atients (14%) had received prior radiotherapy at ini-
ial presentation or as salvage therapy for relapse.
onventional salvage chemotherapy was given to all
elapsed patients (20 patients [71%] received dexa-
ethasone, cytarabine, and cisplatin and 8 patients
29%] received etoposide, methylprednisone, cytara-
able 1. Patient Characteristics
Item Frequency (%)
atients, n 28
ge, median (range) 30 (16-50)
ex
Male 19 (68)
Female 9 (32)
tage at diagnosis
II 5 (18)
III 15 (54)
IV 8 (28)
symptoms at diagnosis 12 (43)
xtranodal disease at diagnosis
Yes 9 (32)
No 19 (68)
istology
Lymphocyte predominance 2 (7)
Nodular sclerosis 5 (18)
Mixed cellularity 13 (46)
Lymphocyte depletion 8 (29)
one marrow involvement
Yes 7 (25)
No 21 (75)ine, and cisplatin). Most patients received 2-3 cycles
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M. Mabed and S. El-Sharawy944f salvage therapy to achieve maximal response before
ransplantation.
The patient characteristics at time of transplanta-
ion are presented in Table 3. Eight patients (28%)
eceived transplants in second CR. Seventeen patients
61%) received transplants after second or subsequent
elapse. The median duration of ﬁrst CR to ﬁrst re-
apse was 10 months (range, 5-16 months). The me-
ian time from diagnosis to transplantation was 13
onths (range, 5-20 months). Twelve of relapsed pa-
ients (43%) had sensitive relapse. Three patients
11%) underwent transplantation after induction with
r without salvage chemotherapy or chemoradiother-
py failure. The median Karnofsky Performance Sta-
us score was 90% (range, 80%-100%). Seven patients
25%) had extranodal diseases at time of transplanta-
ion. The median time from diagnosis to transplanta-
ion was 13 months (range, 5-20 months).
obilization of Progenitor Cells (Figure 1)
Patients received a single dose of cyclophospha-
ide (1.5 g/m2) followed after 5 days by 5
g · kg1 · d1 recombinant human granulocyte col-
ny-stimulating factor (G-CSF). Recombinant human
-CSF was continued until the end of leukapheresis.
ollection and Preservation of PBSCs (Figure 1)
After administration of cyclophosphamide, pa-
ients had complete blood cell counts measured daily
nd began leukapheresis when the total white blood
ounts recovered to 3  109/L, usually at the ninth to
he eleventh day from the start of mobilization. Leu-
apheresis was performed daily until the collection of
2 108 mononuclear cells/kg and3 106 CD34
able 2. Chemotherapy Regimen Before Transplantation
Regimen Frequency (%)
o. of chemotherapy regimens,
median (range) 4 (3-8)
nduction chemotherapy
MOPP/ABV 17 (61)
ABVD 6 (21)
C-MOPP 5 (18)
alvage chemotherapy
DHAP 20 (71)
ESHAP 8 (29)
adiation therapy
Yes 4 (14)
No 24 (86)
OPP/ABV indicates cyclophosphamide, vincristine, procarba-
zine, prednisone, doxorubicin, bleomycin, and vinblastine;
ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine;
C-MOPP, cyclophosphamide, vincristine, procarbazine, and
prednisone; DHAP, dexamethazone, cytarabine, and cisplatin;
and ESHAP, etoposide, methylprednisone, cytarabine, and cis-
platin.ells/kg patient weight. The apheresis solution wascid citrate dextrose and the ﬁnal product was stored
t 4°C for a maximum of 72 hours without special
dditives. Viability was assessed by trypan blue dye
xclusion test 24, 48, and 72 hours from harvesting.
onditioning Regimen (Figure 1)
The conditioning regimen for transplantation was
tarted after the end of leukapheresis and given over 2
ays. It contained cyclophosphamide (60 mg · kg1
· d1 for 2 days), etoposide (15 mg · kg1 · d1 for 2
ays), and carboplatin (400 mg/m2 per day for 2 days).
wenty-four hours after the end of chemotherapy, the
on-cryopreserved stem cells were reinfused.
tatistical Analysis
Neutrophil recovery was deﬁned as the ﬁrst of 2
onsecutive days of neutrophil counts 0.5  109/L.
latelet recovery was deﬁned as the ﬁrst of 7 consec-
tive days with a platelet count 20  109/L unsup-
orted by transfusion. DFS was deﬁned as the time
rom PBSC reinfusion to the time of disease progres-
ion or last follow-up. Overall survival (OS) was de-
ned as the time from reinfusion of PBSCs to death or
ate of last follow-up. Survival distributions were as-
essed with Kaplan-Meier estimates [9].
ESULTS
iability Assessment (Table 4)
Trypan blue dye exclusion showed90% viability
n all samples tested 24, 48, or 72 hours from harvest-
ng.
able 3. Patient Characteristics at Time of Transplantation
Item Frequency (%)
tatus at transplantation
Second CR 8 (28)
Relapse
Sensitive relapse 12 (43)
Resistant relapse 5 (18)
Refractory disease 3 (11)
uration of first CR, median
(range) 10 (5-16 months)
ime from diagnosis to transplant,
median (range) 13 (5-20 months)
PS score
80 7 (25)
90 15 (54)
100 6 (21)
xtranodal disease
Yes 7 (25)
No 21 (75)
R indicates complete remission; KPS, Karnofsky Performance
Status.
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High-Dose Chemotherapy/PBSC Rescue for Refractory/Relapsed HD 945ematopoietic Recovery (Table 4)
Successful PBSC collection was achieved in all
atients. The median number of CD34 cells col-
ected from patients was 6.4 106/kg (range, 3.8-24.6
106/kg). The use of such G-CSF mobilized PBSCs
fter high-dose myeloablative therapy resulted in a
apid, complete, and sustained hematopoietic recovery
n all patients. The median time to achieve an absolute
eutrophil count 0.5  109/L was 13 days (range,
-18 days). The median time to a self-sustained plate-
et count20 109/L was 15 days (range, 7-20 days).
ssessment of Response
All patients were assessable for response. No early
eaths had occurred. At 30 days, 19 patients (68%),
ncluding the 8 patients who underwent transplanta-
ion in CR, were in CR. Five patients (19%) achieved
R. Two patients (7%) had stable disease and 2 pa-
ients (7%) did not respond. Without additional treat-
ent, restaging at 3 months showed 22 patients (78%)
n CR, 1 patient (4%) in PR, 1 patient (4%) with
                                                                                                     High dose chemother
                                                                                           
                                                                                         
                                                                                          CY=60mg/kg 
                                                                                                  Etop=15mg/kg 
                                                                                                Carb=400mg/m2 
                                                                                                       CY=60mg/k
                                                                                                       Etop=15mg
                                                                                                     Carb=400mg
      CY=1.5gm/m2                                                                   
                                                                                                   
                                                                     G-CSF                                          
                                                                                        
                 ____ _ __  __  ______________ __  __  _____________________
________________________________    
ays   day -10                            day -5                   day -3      -2              -1     
                                                                                                                        St
                                                                                   Leukaphersis                 
                                                                                                                           
igure 1. Schema of procedure. Carb indicates carboplatin; CY, cyc
actor; Neutro, neutrophil count.
able 4. Viability Data
Viability % CD34
Cells 
106/kg24 hrs 48 hrs 72 hrs
edian 97.6 96 95 6.4
ange 92.4-99.4 91.6–98 91–96 3.8–24.6BC indicates red blood cell.table disease, and 4 patients (14%) with disease pro-
ression.
S and DFS
Twelve of the 28 patients (43%) were alive and
isease free at a median follow-up of 16 months
range, 9-86 months) for all surviving patients. The
stimated 2-year OS and DFS for all patients were
5% and 42%, respectively (Figure 2). Thirteen pa-
ients died of relapse or progressive disease, 2 patients
ied of infection, and 1 patient was still surviving in
elapse by the time of analysis. No evidence of graft
ailure was present by the time of death of any patient.
he median time to relapse was 10 months (range,
-28 months) from PBSC infusion.
ISCUSSION
High-dose therapy followed by autologous stem
ell transplantation has been shown to produce long-
erm DFS in selected patients with advanced refrac-
                                                                    G-CSF 
_________  _  _  _  _   _______  __  __     
                                   day+5                                                  Neutro> 500/µL
Infusion 
 
   
phamide; Etop, etoposide; G-CSF, granulocyte colony-stimulating
ime to
latelets
ecovery
(days)
Time to
Neutrophiles
Recovery
(days)
No. of RBCs
Transfusions
No. of
Platelets
Transfusions
15 13 5 7
7–20 7–18 4–7 5–9apy 
g 
/kg 
/m2 
             
______
        0   
em cell 
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M. Mabed and S. El-Sharawy946ory or relapsed HD. Approximately 40% to 72%
ong-term DFS has been reported from several series
10]. However, the conventional procedures for col-
ection and freezing of PBSCs are time-consuming
nd expensive. Methods to simplify bone marrow
ransplantation procedures are needed mainly in de-
eloping countries.
Refrigerated storage for short-term preservation
f bone marrow is an alternative to cryopreservation.
n an in vitro analysis, the stem cell population was
oncentrated and the nucleated cell recovery, viability,
nd colony-forming potential were compared after
efrigerated storage of whole bone marrow and buffy
oat with cryopreserved bone marrow stored for the
ame interval. Although the nucleated cell recovery
or cryopreserved marrow was signiﬁcantly greater
han that for refrigerated storage, the viability and
olony-forming potential of the refrigerated storage
ere superior or equivalent, independent of prior pro-
essing [8]. Conversely, no clinically meaningful vari-
tion in post-transplantation course and engraftment
inetics between refrigerated storage and cryopre-
erved stem cells was found [8,11,12].
A simpliﬁed schedule of high-dose chemotherapy
onsisting of melphalan plus VP16 given over 12-18
ours in addition to autologous non-cryopreserved
utologous bone marrow transplant was used for
reatment of patients with relapsed and refractory dis-
ase and as ﬁrst-line treatment for poor-prognosis
D. This high-dose chemotherapy with short-dura-
ion chemotherapy regimen and non-cryopreserved
one marrow was an effective and safe treatment mo-
ality for patients with relapsed and poor-prognosis
Figure 2: kaplan-M
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Figure 2. Kaplan-Meier product estimate of the cumD [13]. Our study conﬁrms that non-frozen stemells are useful to support patients with HD that is
reated with myeloablative therapies.
One potential advantage to refrigerated storage is
hat it may provide an opportunity for extended ex-
osure to growth factors and/or purging agents in
itro before transplantation [8]. Storage of PBSCs
vernight at 4°C allows pooling of consecutive-day
ollections, resulting in decreased costs and process-
ng time without compromising neutrophil and plate-
et engraftment after infusion of CD34-selected pro-
enitor cells [14].
The use of such non-cryopreserved stem cells may
ield cost savings when performing autologous stem
ell transplantation. In our institution, the cost of the
ntire transplantation was approximately 12% less
hen using non-cryopreserved cells than when using a
omparable treatment regimen with cryopreserved
ells. The difference is mostly attributed to the lower
ost of storing and infusing the non-cryopreserved
ells. Over a 10-year period, Ruiz-Arguelles et al
15,16] performed autotransplantations using non-
ryopreserved and unmanipulated PBSCs mobilized
rom the bone marrow to the peripheral blood by
eans of ﬁlgrastim and using a single-day condition-
ng regimen with high-dose (200 mg/m2) melphalan.
heir simpliﬁed method to perform autografting in
atients and avoid cryopreservation of cells also re-
ulted in a decrease in the cost of the autologous
ematopoietic stem cell transplantation methods
15,16]. Therefore, it may represent a suitable ap-
roach in the management of patients requiring an
utologous stem cell transplant in developing coun-
ries.
duct estimate of the
 of DFS and OS
onths
1008060
probability of DFS (dashed line) and OS (solid line).eier pro
obability
ime in mMost studies have used a high-dose combination
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High-Dose Chemotherapy/PBSC Rescue for Refractory/Relapsed HD 947hemotherapy regimen. The most commonly used
ombinations are cyclophosphamide, carmustine, and
toposide [17,18] or bis-chloroethyl-nitrosourea, car-
ustine (BCNU), etoposide, cytarabine, and melpha-
an [19,20]. Excellent results were reported with the
ddition of cisplatin to a modiﬁed regimen of cyclo-
hosphamide, carmustine, and etoposide [21,22]. To-
al body irradiation in combination with high-dose
yclophosphamide was used especially for those who
ad not received previous radiotherapy [23,24]. Hy-
erfractionated total lymphoid irradiation in combi-
ation with high-dose etoposide and cyclophospha-
ide has been shown to be efﬁcacious in previously
nirradiated patients with relapsing or chemotherapy-
esistant HD [5]. At present, there is no evidence to
uggest the superiority of 1 regimen over another.
In this study, we used the combination of cyclo-
hosphamide, etoposide, and carboplatin followed by
BSCT.
Cyclophosphamide is a member of the oxazaphos-
horine group of nitrogen mustard derivatives and is
he most widely used alkylating agent in bone marrow
ransplantation, based in part on its broad range of
ntineoplastic activity and immunomodulatory prop-
rties [25]. The pharmacokinetics of unchanged cy-
lophosphamide in the plasma have shown consider-
ble interpatient variability, with a terminal half-life of
-9 hours [26]. Etoposide (VP16) is the podophyllo-
oxin derivative most commonly used in standard clin-
cal oncologic practice and as a component of many
igh-dose chemotherapy regimens for hematopoietic
alignancies [27]. Caution must be exercised when
igh-dose etoposide is delivered immediately after
igh-dose cisplatin, because acute cisplatin exposure
an reduce the systemic clearance of etoposide by
pproximately 25%, leading to a substantially greater
han expected etoposide area under the curve and
oxicity level [28]. In contrast, high-dose carboplatin
xposure may not alter the disposition of high-dose
toposide [29]. The pharmacokinetics of etoposide
ave been studied over the entire range of intravenous
egimens, from 0.1 to 3 g/m2. Etoposide, which is
ighly protein bound, has a biexponential decay with
mean terminal half-life (t1/2)of 4-8 hours after high-
ose therapy [30]. Carboplatin is an analog of cisplatin
n which the 2 chloride ligands are replaced by the
arboxylate moiety. Carboplatin disappearance is
aused, almost exclusively, by renal excretion [31].
he disappearance of carboplatin from plasma is char-
cterized by a triexponential decay, with a t1/2 of
pproximately 20 min, a t1/2 of about 1.5 hours, and
t1/2	 of approximately 7.5-20 hours. Essentially, all
nbound platinum species have been cleared from the
lasma within 24 hours after completion of a high-
ose carboplatin infusion [32].
The combination was beneﬁcial in the treatment
f relapsed or refractory HD. DFS over 2 years can bechieved in some patients. The results are at least
quivalent to other published regimens including
hose based on total body irradiation and to other
tudies with nearly the same follow-up time [33]. The
egimen appears to be a particularly attractive alter-
ative for patients who have received dose-limiting
adiotherapy and it should be evaluated further in
rospective, randomized trials. Being short term, it
llows the use of non-cryopreserved stem cell trans-
lantation.
In conclusion, this simpliﬁed approach for per-
orming autografting in patients, avoiding purging
rocedures, and cryopreservation of the cells is feasi-
le and results in a substantial decrease of the cost of
utologous hematopoietic stem cell transplantation
ethods. On the other hand, the results of the study
re encouraging in so far that the DFS and OS are
omparable to other protocols of high dose chemo-
herapy and PBSCT.
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